MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Clinical trials for MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost stem cell transplant success in aggressive blood cancers
Disease control Recruiting nowThis study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 11:50 UTC
-
New drug cocktail aims to halt deadly blood cancer progression
Disease control Recruiting nowThis study tests whether adding iadademstat to standard ASTX727 therapy improves outcomes for people with advanced myeloproliferative neoplasms (MPNs), a group of blood cancers. About 62 adults with accelerated or blast-phase MPNs will be randomly assigned to receive ASTX727 alon…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC